These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 34046846)

  • 1. Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice.
    Royston M; Kielhorn A; Weycker D; Shaff M; Houde L; Tanvir I; Bhattacharyya S; Levy M
    Neurol Ther; 2021 Dec; 10(2):767-783. PubMed ID: 34046846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Economic Burden of Relapses in Neuromyelitis Optica Spectrum Disorder: A Real-World Analysis Using German Claims Data.
    Knapp RK; Hardtstock F; Wilke T; Maywald U; Deiters B; Schneider S; Mouchet J
    Neurol Ther; 2022 Mar; 11(1):247-263. PubMed ID: 34940956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The costs of care from a US claims database in patients with neuromyelitis optica spectrum disorder.
    Exuzides A; Sheinson D; Sidiropoulos P; Gholizadeh S; Magrini F; Surinach A; Cook L; Meyer CS; Yeaman MR
    J Neurol Sci; 2021 Aug; 427():117553. PubMed ID: 34224957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring the economic burden of neuromyelitis optica spectrum disorder in Colombia.
    Gil-Rojas Y; Amaya-Granados D; Quiñones J; Robles A; Samacá-Samacá D; Hernández F
    Mult Scler Relat Disord; 2024 Feb; 82():105376. PubMed ID: 38141561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I
    Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis Optica Spectrum Disorders in Africa: A Systematic Review.
    Musubire AK; Derdelinckx J; Reynders T; Meya DB; Bohjanen PR; Cras P; Willekens B
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34663674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder.
    Exuzides A; Sheinson D; Sidiropoulos P; Magrini F; Gholizadeh S; Surinach A; Cook L; Meyer CS; Yeaman M
    J Neurol Sci; 2021 Aug; 427():117530. PubMed ID: 34111762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation.
    Khalilidehkordi E; Clarke L; Arnett S; Bukhari W; Jimenez Sanchez S; O'Gorman C; Sun J; Prain KM; Woodhall M; Silvestrini R; Bundell CS; Abernethy D; Bhuta S; Blum S; Boggild M; Boundy K; Brew BJ; Brown M; Brownlee W; Butzkueven H; Carroll WM; Chen C; Coulthard A; Dale RC; Das C; Fabis-Pedrini MJ; Fulcher D; Gillis D; Hawke S; Heard R; Henderson APD; Heshmat S; Hodgkinson S; Kilpatrick TJ; King J; Kneebone C; Kornberg AJ; Lechner-Scott J; Lin MW; Lynch C; Macdonell RAL; Mason DF; McCombe PA; Pereira J; Pollard JD; Ramanathan S; Reddel SW; Shaw C; Spies J; Stankovich J; Sutton I; Vucic S; Walsh M; Wong RC; Yiu EM; Barnett MH; Kermode AG; Marriott MP; Parratt J; Slee M; Taylor BV; Willoughby E; Brilot F; Vincent A; Waters P; Broadley SA
    Front Neurol; 2020; 11():537. PubMed ID: 32612571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
    Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
    Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentric clinical and epidemiological comparison of neuromyelitis optica spectrum disorder with multiple sclerosis from India.
    Gupta S; Rehani V; Acharya R; Purohit P; Anadure R; Ahmad F; Soni R; Gupta A; Hiremath R
    Mult Scler Relat Disord; 2021 Jan; 47():102616. PubMed ID: 33166808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders.
    Amaral JM; Talim N; Kleinpaul R; Lana-Peixoto MA;
    Mult Scler Relat Disord; 2020 Jun; 41():102045. PubMed ID: 32179485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
    Espiritu AI; Pasco PMD
    Mult Scler Relat Disord; 2019 Aug; 33():22-32. PubMed ID: 31136907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study.
    Jiao Y; Cui L; Zhang W; Zhang C; Zhang Y; Zhang X; Jiao J
    BMC Neurol; 2018 Apr; 18(1):47. PubMed ID: 29688841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity.
    Long Y; Liang J; Wu L; Lin S; Gao C; Chen X; Qiu W; Yang Y; Zheng X; Yang N; Gao M; Chen Y; Wang Z; Su Q
    Front Neurol; 2017; 8():62. PubMed ID: 28293214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life.
    Fujihara K; Hattori S; Kleiter I; Levy M; Matsuda Y; Mitsutake A; Haramura M; Palace J; Yamamura T;
    J Neurol Sci; 2021 Sep; 428():117546. PubMed ID: 34252701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort.
    Tkachuk V; Balbuena Aguirre ME; Alonso R; Barboza A; Liwacki SDV; Mainella C; Rojas JI; Silva BA; Tavolini D; Zanga G; López P; Delgado Garcia G; Carnero Contentti E
    Mult Scler Relat Disord; 2023 Feb; 70():104485. PubMed ID: 36610362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of neuromyelitis optica spectrum disorder attacks in different age groups and sexes depending on the status of immunosuppressive therapy: A retrospective cohort study.
    Luo W; Shi Z; Kong L; Wang X; Zhou H
    Eur J Neurol; 2024 Mar; 31(3):e16178. PubMed ID: 38117536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
    Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
    Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.